According to Future Market Insights, the global Multiple Unit Pellet Systems market will be worth US$ 3.58 billion by 2022. Between 2022 and 2032, it is expected to develop at a 3.5% CAGR, with a market valuation of US$ 5.07 billion in 2032.
Multi-particulate pellet formulations (MUPS) combine the benefits of pellet-filled capsules and tablets. When ingested as tablets, MUPS dissolve swiftly into their subunits and begin diffusing throughout the stomach and small intestine.
A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15446
MUPS systems have advantages over basic tablets or capsules, such as better dose management and less irritation of the digestive mucosa caused by simple drug disintegration. The multiparticulate technology enables the administration of drugs that would otherwise be incompatible. Because of their strong patient compliance, these dosage forms are gaining transactions during the predicted term.
In contrast to traditional delivery systems, prolonged or delayed-release MUPS formulations disseminate medications at a predetermined rate, hence extending the therapeutic effect. In addition, delayed release of multi-particulate formulations may be used in intestinal drug delivery systems to reduce dose dumping and dosage variability across people.
Key Takeaways from Market Study
- Extended-release dosage forms are the market leader in terms of formulation, accounting for around 47.1% of the value share in 2021.
- By dosage form, capsules lead the global Multiple Unit Pellet Systems market and are expected to grow at a CAGR of 3.3% through 2022 and beyond.
- The proton pump inhibitors market is expected to grow at a 3.6% CAGR over the forecast period.
- By 2032, hospital pharmacies will account for roughly 31.4% of overall demand.
- North America is expected to dominate the global MUPS market, with the US accounting for a large share.
“Increasing demand for gastro retentive drug delivery systems and rapid rise in demand for modified release MUPS products, is set to propel the demand of Multiple Unit Pellet Systems across the globe,” says an analyst of future market insights.
For critical insights on this market, request to ask an expert here@ https://www.futuremarketinsights.com/ask-question/rep-gb-15446
Market Competition
Leading companies in the market for MUPS are implementing a variety of key category, such as new launches, mergers and acquisitions, partnerships, and collaborations, to boost their market presence and expand their existing product portfolio.
- For example, Perrigo Company plc’s Proton pump inhibitor including delayed-release Mini Capsule, 20 mg OTC obtained official approval from the USFDA in May 2022. The drug will be sold under store brand names that are similar to the pharmacy’s Prilosec OTC.
- In March 2020, SPI Pharma added Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald, and Mannogem Onyx to its line of Mannogem Mannitol products for usage in a variety of patient-friendly oral dose forms. Manufacturers may effectively construct complex dosage forms, such as MUPS and controlled-release ODTs, with the help of Mannogem XL Opal and Ruby.
Key Players:
- AstraZeneca plc
- Merck KGaA
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Galderma SA
- Novartis AG
- GlaxoSmithKline Plc
- Perrigo Company Plc.
- Cipla Ltd.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Ltd.
- Eli Lilly and Company
- Dr. Reddy’s Laboratories Ltd.
- Endo International Inc.
- Mylan Pharmaceuticals Inc.
- Teva Pharmaceuticals Ltd.
- AbbVie (Allergan)
- GlaxoSmithKline Plc
- Bayer AG
More Insights Available
The North American region is expected to dominate the multi-unit pellet system market due to the presence of a well-established pharmaceutical industry, high healthcare expenditure, and favorable government initiatives to promote drug development. The United States is the largest market for MUPS in the region.
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/15446
Key Market Segments Covered in Multiple Unit Pellet Systems Industry Research
By Formulation:
- Extended Release Dosage Form
- Delayed Release Dosage Form
- Delayed Release Orodispersible Dosage Form
- Others
By Dosage Form:
- Tablets
- Capsules
- Sachets
- Others
By Drug Class:
- Anti-Hypertensive
- Proton Pump Inhibitors
- Antibiotics
- Analgesics
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
